<DOC>
	<DOCNO>NCT01199068</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability CS-7017 administer orally twice day combination erlotinib , assess pharmacokinetics CS-7017 combination erlotinib .</brief_summary>
	<brief_title>CS-7017 Combination With Erlotinib Subjects With Stage IIIb/IV Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm unresectable locally advanced metastatic ( stage IIIb IV ) Nonsmall Cell Lung Cancer ( NSCLC ) Recurrent disease ( either response treatment subsequent relapse objective response ) progress firstline platinum base therapy Male female ≥ 18 year age Anticipation 3 month survival Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≤ 1 Adequate organ bone marrow function Prior Tyrosine Kinase Inhibitor ( TKI ) therapy Anticipation need major surgical procedure radiation therapy study Remaining influence previous therapy radiotherapy , surgery , immunotherapy within 4 week prior start study treatment Treatment anticancer medication within 4 week study treatment , currently enrol another investigational drug study , enrol another investigational drug study within 4 week start treatment History follow event within 6 month prior start study treatment : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) class ≥I Congestive Heart Failure ( CHF ) , cerebrovascular accident cerebral infarction , pulmonary embolism , deep vein thrombosis , clinically significant thromboembolic event ; clinically significant pulmonary disease ( eg , severe ChronicObstructive Pulmonary Disease ( COPD ) asthma ) Severe edema , ascites fluid , pericardial pleural effusion pericardial involvement tumor within 6 month prior start study treatment , require steroid therapy/ diuretic therapy Subjects brain metastasis ( define untreated , symptomatic require steroid anticonvulsant medication control associate symptom ) Subjects clinically significant active infection require antibiotic therapy , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) positive receive antiretroviral therapy Subjects malabsorption syndrome , chronic diarrhea ( last 4 week ) , inflammatory bowel disease , partial bowel obstruction Diabetes mellitus require insulin , history poor serum glucose control use noninsulin diabetes medication Treatment Thiazolidinedione ( TZDs ) within 4 week prior start study treatment History second malignancy , exception situ cervical cancer adequately treat basal cell squamous cell carcinoma skin Poorlycontrolled blood pressure judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>PPAR gamma agonist</keyword>
	<keyword>Tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Antineoplastic Agent</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Neoplasms</keyword>
</DOC>